PD-0325901

PD-0325901

Contact us: [email protected]

PD-0325901
1643-5 each
EUR 444

PD 0325901
GL5463-1 1
EUR 68.9

PD 0325901
GL5463-25 25
EUR 228.1

PD 0325901
GL5463-5 5
EUR 98.4

EZSolution? PD-0325901, Sterile-Filtered
1990-1 each
EUR 326.4

PD-1/PD-L1 Inhibitor 2
B1050-25 each
EUR 679.2

PD-1/PD-L1 Inhibitor 2
B1050-5 each
EUR 242.4

PD-1/PD-L1 Inhibitor 1
B1213-25 each
EUR 679.2

PD-1/PD-L1 inhibitor 2
B6023-25 25 mg
EUR 525.6
Description: PD-1/PD-L1 inhibitor 2 is a PD-1/PD-L1 interaction inhibitor.

PD-1/PD-L1 inhibitor 2
B6023-5 5 mg
EUR 205.2
Description: PD-1/PD-L1 inhibitor 2 is a PD-1/PD-L1 interaction inhibitor.

PD-1/PD-L1 inhibitor 1
B6172-25 25 mg
EUR 543.6
Description: IC50: 0.006-0.10 ?MPD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor.Plenty of studies show that blocking the PD-1/PD-Ll interactions can lead to the restorage and augment of T cell activation in many systems.

PD-1/PD-L1 inhibitor 1
B6172-5 5 mg
EUR 201.6
Description: IC50: 0.006-0.10 ?MPD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor.Plenty of studies show that blocking the PD-1/PD-Ll interactions can lead to the restorage and augment of T cell activation in many systems.

PD-166866
B2223-25 each
EUR 810

PD-166866
B2223-5 each
EUR 248.4

PD-146176
B2313-25 each
EUR 810

PD-146176
B2313-5 each
EUR 248.4

PD-168393
B2352-25 each
EUR 496.8

PD-168393
B2352-5 each
EUR 170.4

PD 169316
B1703-25 each
EUR 652.8

PD 169316
B1703-5 each
EUR 210

PD 151746
B4791-100 100 mg
EUR 714
Description: PD 151746 is a potent and selective inhibitor of calpain with Ki value of 0.26 ?M for ?-Calpain. Calpain is a calcium-dependent, non-lysosomal cysteine protease that expressed in mammals and many other organisms.

PD 151746
B4791-25 25 mg
EUR 338.4
Description: PD 151746 is a potent and selective inhibitor of calpain with Ki value of 0.26 ?M for ?-Calpain. Calpain is a calcium-dependent, non-lysosomal cysteine protease that expressed in mammals and many other organisms.

PD 151746
B4791-5 5 mg
EUR 142.8
Description: PD 151746 is a potent and selective inhibitor of calpain with Ki value of 0.26 ?M for ?-Calpain. Calpain is a calcium-dependent, non-lysosomal cysteine protease that expressed in mammals and many other organisms.

PD 151746
B4791-5.1 10 mM (in 1mL DMSO)
EUR 151.2
Description: PD 151746 is a potent and selective inhibitor of calpain with Ki value of 0.26 ?M for ?-Calpain. Calpain is a calcium-dependent, non-lysosomal cysteine protease that expressed in mammals and many other organisms.

PD 334581
B5727-10 10 mg
EUR 583.2

PD 334581
B5727-50 50 mg
EUR 2220

PD 98059
1666-5 each
EUR 189.6

PD 173074
1675-1 each
EUR 164.4

PD 173074
1675-100 each Ask for price

PD 150,606
1906-25 each
EUR 444

PD 150,606
1906-5 each
EUR 164.4

PD 173074
27056 10 mg
EUR 125
Description: PD 173074 inhibited the kinase activity of FGFR1 with an IC50 of 25 nM in vitro, while inhibiting Src, the receptors for insulin, epidermal growth factor (EGF) and PDGF, and several serine/threonine kinases with 1000-fold or higher IC50 values. PD 173074 was an ATP-competitive inhibitor of FGFR1, with a Ki of around 40 nM. PD 173074 inhibited autophosphorylation of FGFR1 and VEGFR2 in a dose-dependent manner with IC50s in the range of 1-5 nM and 100-200 nM, respectively.

PD 184161
C4361-10 10 mg
EUR 339.6
Description: IC50: 10-100 nMPD 184161 is a MEK1/2 inhibitor. The intracellular signaling pathway of mitogen-activated protein kinases is involved in the regulation of various cellular functions.

PD 184161
C4361-25 25 mg
EUR 673.2
Description: IC50: 10-100 nMPD 184161 is a MEK1/2 inhibitor. The intracellular signaling pathway of mitogen-activated protein kinases is involved in the regulation of various cellular functions.

PD 184161
C4361-5 5 mg
EUR 217.2
Description: IC50: 10-100 nMPD 184161 is a MEK1/2 inhibitor. The intracellular signaling pathway of mitogen-activated protein kinases is involved in the regulation of various cellular functions.

PD 166326
C3677-1 1 mg
EUR 193.2
Description: IC50: 8 nM for c-abl PD 166326 is a receptor tyrosine kinase inhibitor.Receptor tyrosine kinases are the high-affinity cell surface receptors for many growth factors, cytokines, as well as hormones.

PD 166326
C3677-10 10 mg
EUR 1128
Description: IC50: 8 nM for c-abl PD 166326 is a receptor tyrosine kinase inhibitor.Receptor tyrosine kinases are the high-affinity cell surface receptors for many growth factors, cytokines, as well as hormones.

PD 166326
C3677-5 5 mg
EUR 661.2
Description: IC50: 8 nM for c-abl PD 166326 is a receptor tyrosine kinase inhibitor.Receptor tyrosine kinases are the high-affinity cell surface receptors for many growth factors, cytokines, as well as hormones.

PD 176252
B7122-10 10 mg
EUR 614.4

PD 198306
B7124-1 1 mg
EUR 151.2
Description: IC50: 8 nM for MEK [1]PD 198306 is a potent, selective and non-ATP competitive MAPK/ERK-kinase (MEK) inhibitor. MEK is a kinase enzyme which phosphorylates mitogen-activated protein kinase (MAPK).

PD 198306
B7124-10 10 mg
EUR 634.8
Description: IC50: 8 nM for MEK [1]PD 198306 is a potent, selective and non-ATP competitive MAPK/ERK-kinase (MEK) inhibitor. MEK is a kinase enzyme which phosphorylates mitogen-activated protein kinase (MAPK).

PD 198306
B7124-5 5 mg
EUR 381.6
Description: IC50: 8 nM for MEK [1]PD 198306 is a potent, selective and non-ATP competitive MAPK/ERK-kinase (MEK) inhibitor. MEK is a kinase enzyme which phosphorylates mitogen-activated protein kinase (MAPK).

PD 135158
B7127-10 10 mg
EUR 583.2

PD 135158
B7127-50 50 mg
EUR 2220

PD 158780
B7130-10 10 mg
EUR 278.4

PD 158780
B7130-25 25 mg
EUR 543.6

PD 158780
B7130-5 5 mg
EUR 181.2

PD 118057
B7203-10 10 mg
EUR 400.8

PD 118057
B7203-50 50 mg
EUR 1491.6

PD 146176
B7208-10 10 mg
EUR 180

PD 146176
B7208-25 25 mg
EUR 344.4

PD 146176
B7208-50 50 mg
EUR 567.6

PD 173212
B7424-10 10 mg
EUR 634.8

PD 173212
B7424-5 5 mg
EUR 451.2

PD 173212
B7424-5.1 10 mM (in 1mL DMSO)
EUR 574.8

PD 161570
B7486-10 10 mg
EUR 544.8

PD 161570
B7486-50 50 mg
EUR 2056.8

PD 150606
A4413-25 25 mg
EUR 513.6
Description: PD 150606 is a specific inhibitor of calpain with Ki value of 0.21 ?M and 0.37 ?M for mu- and m- calpains, respectively [1].

PD 150606
A4413-5 5 mg
EUR 172.8
Description: PD 150606 is a specific inhibitor of calpain with Ki value of 0.21 ?M and 0.37 ?M for mu- and m- calpains, respectively [1].

PD 166793
A4438-10 10 mg
EUR 290.4
Description: Broad spectrum MMP inhibitor. Displays high affinity for MMP-2, -3 and -13 (IC50 values are 4, 7 and 8 nM respectively) and exhibits > 750-fold selectivity over MMP-1, -7 and -9. Attenuates left ventricular remodelling and dysfunction in rat model of heart failure.

PD 166793
A4438-25 25 mg
EUR 597.6
Description: Broad spectrum MMP inhibitor. Displays high affinity for MMP-2, -3 and -13 (IC50 values are 4, 7 and 8 nM respectively) and exhibits > 750-fold selectivity over MMP-1, -7 and -9. Attenuates left ventricular remodelling and dysfunction in rat model of heart failure.

PD 166793
A4438-5 5 mg
EUR 224.4
Description: Broad spectrum MMP inhibitor. Displays high affinity for MMP-2, -3 and -13 (IC50 values are 4, 7 and 8 nM respectively) and exhibits > 750-fold selectivity over MMP-1, -7 and -9. Attenuates left ventricular remodelling and dysfunction in rat model of heart failure.

PD 81723
B6705-10 10 mg
EUR 340.8

PD 81723
B6705-50 50 mg
EUR 1245.6

PD 102807
B6821-10 10 mg
EUR 466.8

PD 102807
B6821-50 50 mg
EUR 1771.2

PD 160170
B6972-10 10 mg
EUR 408

PD 180970
A8606-10 10 mg
EUR 517.2
Description: ATP-competitive inhibitor of p210bcr/abl tyrosine kinase; selectively induces apoptosis in chronic myeloid leukemia (CML) K562 cells. Inhibits in vivo tyrosine phosphorylation of Gab2, CrkL and p210bcr/abl (IC50 values are 80, 80 and 170 nM respectively).

PD 169316
A8689-10 10 mg
EUR 195.6
Description: IC50: A potent, selective and cell-permeable suppressor of p38 MAP kinase, with the IC50 value of 89 nM.PD169316, a specific p38 MAPK inhibitor, blocks signal transduction mediated by both TGF-? and Activin A, but not bone morphogenetic protein (BMP) 4.

PD 169316
A8689-5.1 10 mM (in 1mL DMSO)
EUR 268.8
Description: IC50: A potent, selective and cell-permeable suppressor of p38 MAP kinase, with the IC50 value of 89 nM.PD169316, a specific p38 MAPK inhibitor, blocks signal transduction mediated by both TGF-? and Activin A, but not bone morphogenetic protein (BMP) 4.

PD 169316
A8689-50 50 mg
EUR 595.2
Description: IC50: A potent, selective and cell-permeable suppressor of p38 MAP kinase, with the IC50 value of 89 nM.PD169316, a specific p38 MAPK inhibitor, blocks signal transduction mediated by both TGF-? and Activin A, but not bone morphogenetic protein (BMP) 4.

PD 173074
A8253-10 10 mg
EUR 129.6
Description: PD173074 is a poten and selective fibroblast growth factor receptor (FGFR) inhibitor. Fibroblast growth factor-2 is reported to be able to induce proliferation and chemoresistance in Small cell lung cancer (SCLC) cells.

PD 173074
A8253-5.1 10 mM (in 1mL DMSO)
EUR 142.8
Description: PD173074 is a poten and selective fibroblast growth factor receptor (FGFR) inhibitor. Fibroblast growth factor-2 is reported to be able to induce proliferation and chemoresistance in Small cell lung cancer (SCLC) cells.

PD 173074
A8253-50 50 mg
EUR 254.4
Description: PD173074 is a poten and selective fibroblast growth factor receptor (FGFR) inhibitor. Fibroblast growth factor-2 is reported to be able to induce proliferation and chemoresistance in Small cell lung cancer (SCLC) cells.

PD 173074
A8253-S Evaluation Sample
EUR 97.2
Description: PD173074 is a poten and selective fibroblast growth factor receptor (FGFR) inhibitor. Fibroblast growth factor-2 is reported to be able to induce proliferation and chemoresistance in Small cell lung cancer (SCLC) cells.

PD 145305
C5830-10 10 mg
EUR 513.6
Description: PD 145305 is an inactive analog of PD 150606, a potent and selective calpains inhibitor [1]. Calpain is a class of cytosolic cysteine protease that is activated by elevated intracellular calcium.

PD 145305
C5830-5 5 mg
EUR 315.6
Description: PD 145305 is an inactive analog of PD 150606, a potent and selective calpains inhibitor [1]. Calpain is a class of cytosolic cysteine protease that is activated by elevated intracellular calcium.

PD-ECGF
PR15044 10 ug
EUR 584.4

PD 98,059
GK2140-10MG 10 mg
EUR 206.4

PD 98,059
GK2140-1MG 1 mg
EUR 109.2

PD 98,059
GK2140-50MG 50 mg
EUR 453.6

PD 98,059
GK2140-5MG 5 mg
EUR 164.4

PD 150,606
GL2543-25MG 25 mg
EUR 495.6

PD 150,606
GL2543-5MG 5 mg
EUR 184.8

PD-ECGF
GT15181 100 ug
EUR 631.2

PD 0332991
E1KS1116 5mg
EUR 812.4

PD-166866
HY-101296 10mM/1mL
EUR 165.6

PD-159020
HY-101598 1mg
EUR 1350

PD 123319
HY-10259 5mg
EUR 218.4

PD 169316
HY-10578 10mM/1mL
EUR 306

PD 90780
HY-110166 5mg
EUR 391.2

PD 407824
HY-18961 100mg
EUR 1850.4

PD 151746
HY-19749 50mg
EUR 589.2

PD 117519
HY-100032 5mg
EUR 142.8

PD 150,606
GL2543-25 25
EUR 393.3

PD 150,606
GL2543-5 5
EUR 127.7

PD 98,059
GK2140-1 1
EUR 63

PD 98,059
GK2140-10 10
EUR 151.4

PD 98,059
GK2140-5 5
EUR 98.4

PD 98,059
GK2140-50 50
EUR 369.6

PD-173955
GW0583-1 1
EUR 311.9

PD-173955
GW0583-10 10
EUR 748.1

PD-173955
GW0583-5 5
EUR 492

PD-1:PD-L1 Homogeneous Assay Kit
72014 384 rxns.
EUR 1070
Description: The PD-1:PD-L1 Homogeneous Assay Kit is designed to measure the_x000D_inhibition of PD-1 binding to PD-L1. With this kit, only three simple steps on a microtiter_x000D_plate are required. First, a sample containing PD-1 and an inhibitor of choice is incubated with_x000D_the biotinylated PD-L1 for 60 minutes. Next, acceptor beads are added, then donor beads,_x000D_followed by reading the Alpha-counts.

PD-1:PD-L2 Homogeneous Assay Kit
72015 384 rxns.
EUR 1070
Description: The PD-1:PD-L2 Homogeneous Assay Kit is designed to measure the_x000D_inhibition of PD-1 binding to PD-L2. With this kit, only three simple steps on a microtiter_x000D_plate are required. First, a sample containing PD-1 and an inhibitor of choice is incubated with_x000D_the biotinylated PD-L2 for 60 minutes. Next, acceptor beads are added, then donor beads,_x000D_followed by reading the Alpha-counts.

PD-1:PD-L1 TR-FRET Assay
72032 96 rxns.
EUR 745
Description: The PD-1:PD-L1 TR-FRET Assay is designed to measure the inhibition of PD-1 binding to PD-L1 in a homogeneous 96 reaction format. This FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; a sample containing europium-labeled (Eu) PD-1, dye-labeled acceptor, biotin-labeled PD-L1, and an inhibitor is incubated for two hours. Then, the fluorescence intensity is measured using a fluorescence reader.

PD-1:PD-L1 TR-FRET Assay
72038 384 rxns.
EUR 845
Description: The PD-1:PD-L1 TR-FRET Assay is designed to measure the inhibition of PD-1 binding to PD-L1 in a homogeneous 384 reaction format. This FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; a sample containing europium-labeled (Eu) PD-1, dye-labeled acceptor, biotin-labeled PD-L1, and an inhibitor is incubated for two hours. Then, the fluorescence intensity is measured using a fluorescence reader.

PD-1:PD-L1/PD-L2 Cell-Based Inhibitor Screening Assay Kit
60800 96 rxns.
EUR 1070
Description: The PD-1/PD-L1 Inhibitor Screening Cell-Based Assay is a bioluminescent cell-based assay that can be used to screen and profile inhibitors of PD-1:PD-L1 or PD-1:PD-L2 interaction. The assay consists of two main components:_x000D_ • PD-1 Effector cells (PD-1/NFAT reporter-Jurkat cells): Reporter Jurkat T cells expressing firefly luciferase gene under the control of NFAT response elements and also constitutively expressing human PD-1. These cryopreserved cells are provided in a thaw-and-use format that does not require cell propagation._x000D_ • _x000D_Expression vectors for TCR activator, human PD-L1, and human PD-L2: Transfection-ready vectors are used to transfect cells to create the target cells that overexpress PD-L1 or PD-L2 and an engineered cell surface T cell receptor (TCR) activator._x000D_

PD-1:PD-L2 TR-FRET Assay Kit
72012 384 rxns.
EUR 1070
Description: The PD-1:PD-L2 TR-FRET Assay Kit is designed to measure the inhibition of PD-1 binding to_x000D_PD-L2 in a homogeneous 384 reaction format. Cell signaling through the PD-1 receptor upon_x000D_binding the PD-L2 ligand attenuates immune responses and is exploited by both tumors and_x000D_viruses. This FRET-based assay requires no time-consuming washing steps, making it_x000D_especially suitable for high throughput screening applications. The assay procedure is_x000D_straightforward and simple; a sample containing europium-labeled (Eu) PD-1, dye-labeled_x000D_acceptor, biotin-labeled PD-L2, and an inhibitor is incubated for two hours. Then, the_x000D_fluorescence intensity is measured using a fluorescence reader.

PD-1[Biotinylated]:PD-L1 Homogeneous Assay Kit
72028 384 rxns.
EUR 1070
Description: The PD-1[Biotinylated]:PD-L1 Homogeneous Assay Kit is designed to measure_x000D_the inhibition of PD-1 binding to PD-L1. The PD-1[Biotinylated]:PD-L1 Homogeneous Assay Kit_x000D_comes in a convenient AlphaLISA® format with purified biotinylated PD-1, FLAG-tagged PD-L1,_x000D_and assay buffer to perform a total of 384 reactions. With this kit, only three simple steps on a_x000D_microtiter plate are required. First, a sample containing biotinylated PD-1 and an inhibitor of_x000D_choice is incubated with the FLAG-tagged PD-L1 for 60 minutes. Next, acceptor beads are_x000D_added, then donor beads, followed by reading the Alpha-counts.

Ribosome-inactivating protein PD-L1 / PD-L2 Antibody
20-abx319445
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Ribosome-inactivating protein PD-L1/PD-L2 Antibody
1-CSB-PA306294LA01PJJ
  • EUR 380.40
  • EUR 402.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against Ribosome-inactivating protein PD-L1/PD-L2. Recognizes Ribosome-inactivating protein PD-L1/PD-L2 from Phytolacca dioica. This antibody is Unconjugated. Tested in the following application: ELISA

PD-L1 Protein
20-abx261703
  • EUR 4101.60
  • EUR 393.60
  • EUR 276.00
  • 1 mg
  • 20 ug
  • 5 ug

PD-L1 Protein
20-abx263458
  • EUR 1930.80
  • EUR 393.60
  • EUR 276.00
  • 100 ug
  • 10 ug
  • 2 µg

PD-ECGF Antibody
abx236264-100ug 100 ug
EUR 661.2

PD-166285 dihydrochloride
B2094-25 each
EUR 757.2

PD-166285 dihydrochloride
B2094-5 each
EUR 235.2

PD-L1 (CD274)
100443-1 100 µg
EUR 320
Description: Human secreted Programmed Cell Death 1 Ligand 1 (PD-L1) protein, also known as CD274, PDCD1L1, and B7 homolog 1 (B7-H1), GenBank Accession No. NM_014143, a.a. 19-239, expressed in an E. coli expression system. MW = 25 kDa.

PD-L1 (CD274)
100443-2 1 mg
EUR 2720
Description: Human secreted Programmed Cell Death 1 Ligand 1 (PD-L1) protein, also known as CD274, PDCD1L1, and B7 homolog 1 (B7-H1), GenBank Accession No. NM_014143, a.a. 19-239, expressed in an E. coli expression system. MW = 25 kDa.

PD 153035 Hydrochloride
1656-2 each
EUR 189.6

PD-1 Antibody
24505-100ul 100ul
EUR 468

PD-1 Antibody
24506-100ul 100ul
EUR 468

EZSolution? PD 98059
1783-5 each
EUR 189.6

PD 98059, >99%
BC064-010 10mg
EUR 278.4

PD 98059, >99%
BC064-025 25mg
EUR 360

PD 98059, >99%
BC064-050 50mg
EUR 537.6

PD 144418 oxalate
B7125-10 10 mg
EUR 408

PD 144418 oxalate
B7125-50 50 mg
EUR 1531.2

PD 168568 dihydrochloride
B7420-10 10 mg
EUR 369.6

PD 168568 dihydrochloride
B7420-50 50 mg
EUR 1363.2

PD 0332991 (Palbociclib)
B7798-25 25 mg
EUR 184.8
Description: PD-0332991 is selective and oral inhibitor of cyclin-dependent kinase 4/6 with IC50 values of 11nM and 16nM, respectively for CDK4 and CDK6 [1].PD-0332991 is a highly specific inhibitor of CDK4/6.

PD 0332991 (Palbociclib)
B7798-5 5 mg
EUR 129.6
Description: PD-0332991 is selective and oral inhibitor of cyclin-dependent kinase 4/6 with IC50 values of 11nM and 16nM, respectively for CDK4 and CDK6 [1].PD-0332991 is a highly specific inhibitor of CDK4/6.

PD 0332991 (Palbociclib)
B7798-S Evaluation Sample
EUR 97.2
Description: PD-0332991 is selective and oral inhibitor of cyclin-dependent kinase 4/6 with IC50 values of 11nM and 16nM, respectively for CDK4 and CDK6 [1].PD-0332991 is a highly specific inhibitor of CDK4/6.

PD-L1 Antibody
4059-002mg 0.02 mg
EUR 206.18
Description: PD-L1 plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, PD-L1 modulates the activation threshold of T-cells and limits T-cell effector response (1). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (2,3). Through a yet unknown activating receptor, it may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (4).

PD-L1 Antibody
4059-01mg 0.1 mg
EUR 523.7
Description: PD-L1 plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, PD-L1 modulates the activation threshold of T-cells and limits T-cell effector response (1). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (2,3). Through a yet unknown activating receptor, it may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (4).

PD-L1 Peptide
4059P 0.05 mg
EUR 197.7
Description: (IN) PD-L1 peptide

PD-L2 Antibody
4063-002mg 0.02 mg
EUR 206.18
Description: PD-L2 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by co gnate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2, both of which are thought act as a negative regulator of T cell activation. However, it has been suggested that PD-L2 can act to stimulate an immunogenic response through and alternative receptor from PD-1.

PD-L2 Antibody
4063-01mg 0.1 mg
EUR 523.7
Description: PD-L2 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by co gnate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2, both of which are thought act as a negative regulator of T cell activation. However, it has been suggested that PD-L2 can act to stimulate an immunogenic response through and alternative receptor from PD-1.

PD-L2 Peptide
4063P 0.05 mg
EUR 197.7
Description: (IN) PD-L2 peptide

PD-1 Antibody
4065-002mg 0.02 mg
EUR 206.18
Description: PD-1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases.

PD-1 Antibody
4065-01mg 0.1 mg
EUR 523.7
Description: PD-1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases.

PD-1 Peptide
4065P 0.05 mg
EUR 197.7
Description: (CT) PD-1 peptide

PD-1 Antibody
4067-002mg 0.02 mg
EUR 206.18
Description: PD-1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases.

PD-1 Antibody
4067-01mg 0.1 mg
EUR 523.7
Description: PD-1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases.

PD-1 Peptide
4067P 0.05 mg
EUR 197.7
Description: (IN) PD-1 peptide

PD 123319 ditrifluoroacetate
A3704-10 10 mg
EUR 250.8
Description: Description:IC50 Value: 1.2 ±0.4 mM (Inhibition of adenylyl cyclase elicited by 0.1 microM Ang II) [2]PD 123319 ditrifluoroacetate is a potent, selective, non-peptide angiotensin AT2 receptor antagonist.

PD 123319 ditrifluoroacetate
A3704-25 25 mg
EUR 489.6
Description: Description:IC50 Value: 1.2 ±0.4 mM (Inhibition of adenylyl cyclase elicited by 0.1 microM Ang II) [2]PD 123319 ditrifluoroacetate is a potent, selective, non-peptide angiotensin AT2 receptor antagonist.

PD 123319 ditrifluoroacetate
A3704-5 5 mg
EUR 205.2
Description: Description:IC50 Value: 1.2 ±0.4 mM (Inhibition of adenylyl cyclase elicited by 0.1 microM Ang II) [2]PD 123319 ditrifluoroacetate is a potent, selective, non-peptide angiotensin AT2 receptor antagonist.

PD 123319 ditrifluoroacetate
A3704-50 50 mg
EUR 787.2
Description: Description:IC50 Value: 1.2 ±0.4 mM (Inhibition of adenylyl cyclase elicited by 0.1 microM Ang II) [2]PD 123319 ditrifluoroacetate is a potent, selective, non-peptide angiotensin AT2 receptor antagonist.

PD 168077 maleate
B6578-10 10 mg
EUR 362.4

PD 168077 maleate
B6578-50 50 mg
EUR 1315.2

PD-L1 Antibody
49251-100ul 100ul
EUR 399.6

PD-L1 Antibody
49251-50ul 50ul
EUR 286.8

PD-L1 Peptide
46-156P 0.1 mg
EUR 405.6
Description: CD274 / PD-L1 Peptide

PD-123319 ditrifluoroacetate
9640-25 each
EUR 757.2

PD-123319 ditrifluoroacetate
9640-5 each
EUR 235.2

PD-0332991 isethionate
9480-25 each
EUR 652.8

PD-0332991 isethionate
9480-5 each
EUR 210

Anti-PD-L1
DB-241-0.1 100 μl
EUR 469.2
Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated

Anti-PD-L1
DB-241-0.2 200 μl
EUR 675.6
Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated

Anti-PD-L1
DB-241-0.5 500 μl
EUR 889.2
Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated

Anti-PD-L1
DB-241-1 1 ml
EUR 1450.8
Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated

Anti-PD-L1
DB-241-RTU-15 15 ml
EUR 813.6
Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use)

Anti-PD-L1
DB-241-RTU-7 7 ml
EUR 519.6
Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use)

Anti-PD-L1
DB241-RTU-15 15 ml
EUR 813.6
Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use)

Anti-PD-L1
DB241-RTU-7 7 ml
EUR 519.6
Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use)

PD Adaptor Sterile
PIP5086 PK5
EUR 38.4

PD-1 Antibody
P1001-01m 0.1m
EUR 198

PD-1 Antibody
P1001-1ml 1ml
EUR 451.2

PD-L1 Antibody
P1013-01m 0.1m
EUR 224.4

PD-L1 Antibody
P1013-1ml 1ml
EUR 807.6

PD-1,CD279
E6TA00107 0.1mg
EUR 411.6

PD-L1, CD274
E6TA00108 0.1mg
EUR 411.6

PD 123319 (ditrifluoroacetate)
HY-10259A 10mg
EUR 258

(+)-PD 128907 hydrochloride
HY-110000 50mg
EUR 901.2

PD-168077 maleate
HY-21098A 10mM/1mL
EUR 211.2

PD-L1 Antibody
R31573 100 ug
EUR 356.15
Description: Programmed death-ligand 1, also known as CD274 or B7-H1 is a protein that in humans is encoded by the CD274 gene. It is a 33-70kDa type 1 transmembrane protein that has been speculated to play a major role in suppressing the immune system during particular events such as pregnancy, tissue allografts, autoimmune disease and other disease states such as hepatitis. Upregulation on tumor MDCs downregulates T-cell immunity and PD-L1 blockade may represent an approach for cancer immunotherapy. It can provide positive costimulatory signals for innate and adaptive immunity and for protection against intracellular bacterial infection. It has been found that PD1/PDL1 pathway may be a good target for restoring antitumor immunity in ovarian cancer.

PD-L1 Antibody
R33263-100UG 100 ug
EUR 339.15
Description: Additional name(s) for this target protein: Programmed cell death 1 ligand 1; CD274

PD-0325901